The use of exosome and immune profiling to analyze a phase 2 study on the addition of patritumab or placebo to cetuximab and a platinum agent for recurrent / metastatic head and neck cancer (R/M HNSCC) patients.
Volume
36
DOI
10.1200/JCO.2018.36.15_suppl.6043
Issue
ISSN
0732-183X